通过对5年的医院经验进行评估，研究锆（Y90）经肝动脉放射性栓塞治疗（TARE）对原发性肝细胞癌（HCC）的临床疗效。本回顾性研究评估了2017年至2021年间，在一个学术医疗中心接受Y90 TARE治疗的88例连续患者。疾病分布中60.2％的患者为双侧叶型，平均病变直径为5.0 ± 3.4cm，77％的参与者为巴塞罗那肝癌临床肝癌分期为B或C。通过检查并评估并发症、肝功能指标、生化学反应和影像学反应来阐明临床疗效。还计算了客观疗效率（ORR）和无进展生存期（PFS）。平均Y90放射剂量为127.8 ± 20.2Gy。治疗后无明显并发症或肝功能损害。在73.9％的α-胎蛋白阳性肿瘤患者中，67.8％的患者在治疗后1个月出现完全或部分生化学反应。在6个月影像学检查中，ORR为83.3％，PFS为9.6 ± 8.5个月。功能结果（东方合作肿瘤组织学组）在治疗后6个月和1年时分别保持或改善了79.6％和76.1％的患者。平均生存期为14.7 ± 12.1个月。在治疗后的6个月，77.3％的患者进入或保持米兰标准，治疗后的1年和2年分别持续持续74.4％和70.0％的患者。Y90-TARE是原发性HCC安全有效的治疗方法。持久的临床疗效进一步作为实现肝移植的现实桥梁，大多数患者能够长期保持米兰标准和功能状态。版权所有©2023年大学放射科医生协会。由Elsevier Inc.出版。保留所有权利。

To examine the clinical outcomes of yttrium-90 (Y90) transarterial radioembolization (TARE) for primary hepatocellular carcinoma (HCC) through the evaluation of a 5-year institutional experience.This retrospective study evaluated 88 consecutive patients with primary HCC receiving Y90 TARE treatment at an academic medical center from 2017 to 2021. Disease distribution was bilobar in 60.2% of patients with an average lesion diameter of 5.0 ± 3.4 cm and Barcelona Clinic Liver Cancer stage B or C in 77% of the participants. Clinical outcomes were elucidated by examination of complications, liver function tests, biochemical response, and radiographic response. Objective response ratio (ORR) and progression-free survival (PFS) were also calculated.The mean administered Y90 radiation dose was 127.8 ± 20.2 Gy. No significant complications or LFT elevations occurred post-therapy. Of the 73.9% of patients with α-fetoprotein-producing tumors, 67.8% experienced a complete or partial biochemical response 1 month post-treatment. The ORR was 83.3% on 6-month imaging and PFS was 9.6 ± 8.5 months. Functional outcomes (Eastern Cooperative Oncology Group) were maintained or improved in 79.6% and 76.1% of patients by 6 months and 1 year post-treatment, respectively. The mean survival was 14.7 ± 12.1 months. At 6 months post-treatment, 77.3% of patients were downstaged to or maintained Milan criteria, which was sustained for 74.4% and 70.0% of patients 1 year and 2 years after treatment, respectively.Y90-TARE is a safe and effective therapy for primary HCC. Enduring outcomes further act as a realistic bridge to liver transplantation, with a majority of patients maintaining Milan criteria and preserving their functional status long term.Copyright © 2023 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.